OCTREOSCAN

Radiopharmaceuticals shouldbe received, used and administered only by authorised persons in designated clinical settings.Their receipt, storage, use, transfer and disposalis subject to the regulations and/or appropriate licences of the local competent official organisations.

Radiopharmaceuticals should be prepared in a manner which satisfies both radiation safety and pharmaceutical quality requirements. Appropriate aseptic precautions should be taken.

The contents of both vials are intended only for use in the preparation of indium (¹¹¹In) Pentetreotide solution for injection and are not to be administered directly to the patient without first undergoing the preparative procedure.

For instructions on reconstitution of the medicinal product before administration, section 12.

If at any time in the preparation of this product the integirty of the vials is compromised they should not be used.

Administration procedures should be carried out in a way to minimise the risk of contamination of the medicinal product and irradiation of the operators. Adequate shielding is mandatory.

The administration of radiopharmaceuticals creates risks for other persons from external radiation or contamination from spill of urine, vomiting, etc. Radiation protection precautions in accordance with national regulations must thereforebe taken.

Instructions for waste disposal:

Unused ¹¹¹In activity or unused Octreoscan should be allowed to decay until the activity has dropped to such a low level that, according to local regulations, it is no longer considered radioactive. Then it may be disposed of as harmless waste. Unused vials with lyophilized pentetreotide may be disposed of as harmless waste.

Any unused medicinalproduct or waste material should be disposed of in accordance with local requirements.

Radiopharmaceuticals shouldbe received, used and administered only by authorised persons in designated clinical settings.Their receipt, storage, use, transfer and disposalis subject to the regulations and/or appropriate licences of the local competent official organisations.

Radiopharmaceuticals should be prepared in a manner which satisfies both radiation safety and pharmaceutical quality requirements. Appropriate aseptic precautions should be taken.

The contents of both vials are intended only for use in the preparation of indium (¹¹¹In) Pentetreotide solution for injection and are not to be administered directly to the patient without first undergoing the preparative procedure.

For instructions on reconstitution of the medicinal product before administration, section 12.

If at any time in the preparation of this product the integirty of the vials is compromised they should not be used.

Administration procedures should be carried out in a way to minimise the risk of contamination of the medicinal product and irradiation of the operators. Adequate shielding is mandatory.

The administration of radiopharmaceuticals creates risks for other persons from external radiation or contamination from spill of urine, vomiting, etc. Radiation protection precautions in accordance with national regulations must thereforebe taken.

Instructions for waste disposal:

Any unused medicinalproduct or waste material should be disposed of in accordance with local requirements.